Abstract
Purpose: This study is performed to investigate the incidence of cemotherapy-induced nausea and vomiting (CINV) for patients (pts) with colorectal cancer received moderately emetogenic chemotherapy. We also assessed whether the medical staff accurately recognized the incidence of CINV in practices.Methods: A prospective observational study of patients receiving the first cycle of oxaliplatin or irinotecan-based chemotherapy was performed. A 7-day diary for CINV was provided to the patients, and the incidence of CINV was recorded daily by themselves. The observed incidence rates of CINV in acute (day1) and delayed (days2-7) were compared with the medical staff's predictions.Results: A total of 191 pts were registered between April 2011 and December 2012. All pts were treated with oxaliplatin-based (n = 175) or irinotecan-based chemotherapy (n = 16). Acute vomiting episode was observed in 4 pts (2.1%), while delayed vomiting was observed in 19 pts (10%). Acute nausea occurred in 14 pts (7.3%), while delayed nausea occurred in 63 pts (33%). Irinotecan significantly induced acute nausea more frequently than oxaliplatin (P = 0.019). The presence of motion sickness was significantly associated with the incidence of acute nausea (P < 0.001) and vomiting (P = 0.003). Antiemetic agents were given according to the guideline to all pts. 58 pts were given a neurokinin-1 (NK-1) receptor antagonist. Pts with NK-1 receptor antagonist showed significantly less incidence of delayed vomiting than pts without one (3% vs 13%, P = 0.048). 30 pts (15.7%) needed rescue antiemetics. Staffs had estimated the incidence of acute CINV in 91 pts (47.6%). However, acute CINV really occurred in 14 pts (7.3%).Conclusions: CINV seems to be controllable with appropriate management, but delayed CINV remains an important problem. The presence of motion sickness should be affected by efficient antiemetic management. The extent of CINV in this patient group seems to be overestimated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
